Acute kidney injury in SARS-CoV-2 infected patients

Fanelli, Vito; Fiorentino, Marco; Cantaluppi, Vincenzo; Gesualdo, Loreto; Stallone, Giovanni; Ronco, Claudio; Castellano, Giuseppe

doi:10.1186/s13054-020-02872-z

Cited by 187 publications

(199 citation statements)

References 15 publications

Supporting

Mentioning

178

Contrasting

Unclassified

Order By: Relevance

“…Acute kidney injury (AKI) has been reported in > 20% of critically ill or deceased COVID-19 patients, a percentage that is consistent in studies from China [136], Italy [137] and United States [10]. It is important to note that AKI, proteinuria, and hematuria have been independently associated with a higher risk of death in COVID-19 patients [138].…”

Section: Kidney Disease In Covid-19mentioning

confidence: 72%

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Sardu

Gambardella

Morelli

et al. 2020

JCM

468

436

View full text Add to dashboard Cite

The symptoms most commonly reported by patients affected by coronavirus disease (COVID-19) include cough, fever, and shortness of breath. However, other major events usually observed in COVID-19 patients (e.g., high blood pressure, arterial and venous thromboembolism, kidney disease, neurologic disorders, and diabetes mellitus) indicate that the virus is targeting the endothelium, one of the largest organs in the human body. Herein, we report a systematic and comprehensive evaluation of both clinical and preclinical evidence supporting the hypothesis that the endothelium is a key target organ in COVID-19, providing a mechanistic rationale behind its systemic manifestations.

show abstract

Section: Kidney Disease In Covid-19mentioning

confidence: 72%

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Sardu

Gambardella

Morelli

et al. 2020

JCM

468

436

View full text Add to dashboard Cite

show abstract

“…The exact clinical presentation of this new Coronavirus disease (COVID-19) is currently expanding, but so far it typically includes a lower respiratory tract infection, fever and fatigue (1, 2), along with less common symptoms including nausea, diarrhea (3,4), anosmia (5), and aches. Serious cases present with pneumonia, acute respiratory distress syndrome (6), and sometimes acute kidney injury (7). Millions of people have been infected worldwide with a current case-fatality ratio between 3.5 to 15% depending on geographic location and factors not yet defined (8).…”

mentioning

confidence: 99%

Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs

Anson

Chapman

Lendy

et al. 2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 has led to over 200,000 deaths thus far. We screened a library of approved antiviral drugs against the two SARS-CoV-2 proteases, 3C-like/main protease (3CLpro/Mpro) and papain-like protease (PLpro), which are essential for viral replication and attractive drug targets. Three HCV protease inhibitors were tested and found to inhibit 3CLpro and PLpro enzymes from Alpha-, Beta- and Gamma-coronaviruses. Anti-HIV drugs had no activity. Boceprevir and telaprevir inhibited 3CLpro, with boceprevir inhibiting eight of nine coronavirus 3CLpro enzymes tested including from SARS-CoV-2, MERS and SARS-CoV. Asunaprevir inhibited PLpro from SARS-CoV-2 and four other coronaviruses. The 1.4 Å X-ray structure of boceprevir bound to 3CLpro was determined to explain its broad-spectrum activity and guide structure-based design of inhibitors of multiple coronaviruses.Authors Brandon J. Anson, Mackenzie E. Chapman, and Emma K. Lendy contributed equally to this work.

show abstract

“…Novel coronavirus pneumonia patients with other comorbidity are relatively severe, and thirty-two percent of them with hypertension, what's more, we also found that patients with hypertension are more likely to develop severe and critical diseases [5]. Chronic kidney injury is also the same, and many dead patients have renal failure, meanwhile, acute kidney injury during novel coronavirus pneumonia course indicates poor prognosis and increases mortality [11].…”

Section: Discussionmentioning

confidence: 61%

Clinical Characteristics of COVID-19 and the Value of Mulbsta Scoring System in Prognosis Evaluation

Wang

Luo

et al. 2020

Preprint

View full text Add to dashboard Cite

BackgroundCOVID-19, a worldwideinfectious disease, has killed more than 420000 people, whichis extremely harmful.MethodsIn this single-center retrospective study, we included the novel coronavirus pneumonia confirmed in our hospital. This study collected the basic information andclinical examination features.ResultsThe enrolled 704 patients were affirmed infected with 2019-nCoV by the test of throat swabs. There are 334 men and 369 women, and gender, age, combined with basic diseasesare distinct in diverse disease classification (p<0.05). From the symptom analysis, the proportion of fever over 38 degrees, dyspnea, fatigue, poor appetite and other symptoms is diverse in different types of diseases (p<0.05). As the severity of the disease increases, the median lymphocyte count decreases, C-reactive protein increase, erythrocyte sedimentation rateincrease, albumin decrease, pleural effusion increase, D-Dimer and NT-proBNP increase significantly (p<0.05).As the disease severity increases, the average value of MuLBSTA score obviously ascend (p<0.05), MuLBSTA scoring system predicts novel coronavirus pneumonia patients' prognosis is still insufficient, and may require additional indicators including anorexia, fatigue, C reactive protein, etc (p<0.05).ConclusionThe MuLBSTA evaluation system has certain value for the evaluation of the disease, but it needs to be improved.

show abstract

Acute kidney injury in SARS-CoV-2 infected patients

Cited by 187 publications

References 15 publications

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence

Broad-spectrum inhibition of coronavirus main and papain-like proteases by HCV drugs

Clinical Characteristics of COVID-19 and the Value of Mulbsta Scoring System in Prognosis Evaluation

Contact Info

Product

Resources

About